Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling
Jagpreet Chhatwal, Qiushi Chen, Rakesh Aggarwal
Infectious Disease Clinics of North America (2018) Vol. 32, Iss. 2, pp. 461-480
Closed Access | Times Cited: 18

Showing 18 citing articles:

Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016
Megan G. Hofmeister, Elizabeth M. Rosenthal, Laurie K. Barker, et al.
Hepatology (2018) Vol. 69, Iss. 3, pp. 1020-1031
Open Access | Times Cited: 443
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
Eli S. Rosenberg, Elizabeth M. Rosenthal, Eric W. Hall, et al.
JAMA Network Open (2018) Vol. 1, Iss. 8, pp. e186371-e186371
Open Access | Times Cited: 164
Vital Signs:Newly Reported Acute and Chronic Hepatitis C Cases ― United States, 2009–2018
A. Blythe Ryerson, Sarah Schillie, Laurie K. Barker, et al.
MMWR Morbidity and Mortality Weekly Report (2020) Vol. 69, Iss. 14, pp. 399-404
Open Access | Times Cited: 142
Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013‐2016
Heather Bradley, Eric W. Hall, Elizabeth M. Rosenthal, et al.
Hepatology Communications (2020) Vol. 4, Iss. 3, pp. 355-370
Open Access | Times Cited: 79
Novel Machine‐Learning Modeling of Facial Trauma Volume With Regional Event and Weather Data
Rahul K. Sharma, Michael R. Papazian, Rory J. Lubner, et al.
Otolaryngology (2025)
Closed Access
Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
Qiushi Chen, Turgay Ayer, Emily D. Bethea, et al.
BMJ Open (2019) Vol. 9, Iss. 6, pp. e026726-e026726
Open Access | Times Cited: 40
Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan
Jagpreet Chhatwal, Qiushi Chen, Xiaojie Wang, et al.
JAMA Network Open (2019) Vol. 2, Iss. 5, pp. e193613-e193613
Open Access | Times Cited: 38
Bridging the gap: Addressing disparities in hepatitis C screening, access to care, and treatment outcomes
Maram Alenzi, Mohammad Almeqdadi
World Journal of Hepatology (2024) Vol. 16, Iss. 8, pp. 1091-1098
Open Access | Times Cited: 2
A Tool to Inform Hepatitis C Elimination: A Case for Hepatitis C Elimination in China
Madeline Adee, Yueran Zhuo, Tiannan Zhan, et al.
Clinical Liver Disease (2021) Vol. 17, Iss. 3, pp. 99-106
Open Access | Times Cited: 7
Epidemiological Modeling of the Impact of Public Health Policies on Hepatitis C: Protocol for a Gamification Tool Targeting Microelimination
Ricardo Baptista‐Leite, Henrique Lopes, Björn Vandewalle, et al.
JMIR Research Protocols (2023) Vol. 12, pp. e38521-e38521
Open Access | Times Cited: 2
1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
Abdelsattar M. Omar, Mahmoud A. Elfaky, Stefan T. Arold, et al.
Biomolecules (2020) Vol. 10, Iss. 3, pp. 479-479
Open Access | Times Cited: 5
Cost-effectiveness of total state coverage for hepatitis C medications
PhD Jonathan S. Levin William V. Padula
The American Journal of Managed Care (2021) Vol. 27, Iss. 5, pp. e171-e177
Closed Access | Times Cited: 4
Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals
María Ángeles Campos Fernández de Sevilla, Marta Gallego Úbeda, Miriam Heredia Benito, et al.
International Journal of Clinical Pharmacy (2019) Vol. 41, Iss. 2, pp. 488-495
Closed Access | Times Cited: 3
Annual trends of hepatitis C virus infection in Manitoba between 1998 and 2018: A focus on special populations
Sai Krishna Gudi, Sherif Eltonsy, Joseph A. Delaney, et al.
Canadian Liver Journal (2023) Vol. 6, Iss. 2, pp. 249-260
Open Access | Times Cited: 1
1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Venue to Inhibit HCV-NS3 Protease
Abdelsattar M. Omar, Mahmoud A. Elfaky, Stefan T. Arold, et al.
(2020)
Open Access | Times Cited: 1
Results of analysis of epidemological indicators of viral hepatitis c in regions of the world as part of activities to improve pharmaceutical provision for patients
А. А. Ноздріна, А. В. Волкова, A. V. Cherkashyna, et al.
ScienceRise Pharmaceutical Science (2022), Iss. 2(36), pp. 72-80
Open Access | Times Cited: 1
ЗНАЧЕННЯ ПОКАЗНИКІВ КЛІНІЧНОГО АНАЛІЗУ КРОВІ ДЛЯ ВИЗНАЧЕННЯ СТУПЕНЯ ФІБРОЗНОГО ПРОЦЕСУ У ХВОРИХ НА ХРОНІЧНИЙ ГЕПАТИТ С
А. Г. Шейко
Інфекційні хвороби (2023), Iss. 4, pp. 29-33
Open Access
Epidemiological Modeling of the Impact of Public Health Policies on Hepatitis C: Protocol for a Gamification Tool Targeting Microelimination (Preprint)
Ricardo Baptista‐Leite, Henrique Lopes, Björn Vandewalle, et al.
(2022)
Open Access
Page 1

Scroll to top